Savant Capital LLC Sells 6,886 Shares of Zoetis Inc. $ZTS

Savant Capital LLC lowered its position in Zoetis Inc. (NYSE:ZTS) by 64.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,830 shares of the company’s stock after selling 6,886 shares during the quarter. Savant Capital LLC’s holdings in Zoetis were worth $482,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. RFG Advisory LLC grew its stake in Zoetis by 4.9% in the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after purchasing an additional 80 shares in the last quarter. YANKCOM Partnership grew its stake in Zoetis by 3.5% in the fourth quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after purchasing an additional 81 shares in the last quarter. Beese Fulmer Investment Management Inc. grew its stake in Zoetis by 2.4% in the third quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock worth $537,000 after purchasing an additional 85 shares in the last quarter. Quest 10 Wealth Builders Inc. grew its stake in Zoetis by 4.7% in the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after purchasing an additional 86 shares in the last quarter. Finally, Financial Engines Advisors L.L.C. grew its stake in Zoetis by 4.4% in the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after purchasing an additional 87 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Activity

In other Zoetis news, Director Michael B. Mccallister acquired 3,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the acquisition, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Paul Bisaro acquired 2,000 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average price of $75.88 per share, with a total value of $151,760.00. Following the acquisition, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders acquired 11,650 shares of company stock worth $886,384. Insiders own 0.22% of the company’s stock.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Investors are refocusing on Zoetis’ longer-term growth story, including its precision-animal-health expansion and planned Neogen animal genomics acquisition, which may be helping the stock rebound.
• Positive Sentiment: Unusual options activity showed increased call buying in ZTS, suggesting some traders are positioning for more upside.
• Neutral Sentiment: Zoetis released its 2025 Sustainability Report, highlighting progress in its “Driven to Care” strategy; this supports the company’s long-term narrative but is unlikely to move the stock much on its own. Article Title
• Negative Sentiment: Multiple law firms announced or expanded securities class action efforts against Zoetis, alleging investors were harmed by concealed FDA safety warnings and competitive market-share erosion; these headlines can weigh on the stock by raising legal and reputational risk. Article Title
• Negative Sentiment: Recent commentary also highlighted Zoetis’ underperformance versus healthcare peers and criticism from commentators, adding to the cautious tone around the name. Article Title

Zoetis Stock Up 2.6%

Shares of NYSE ZTS opened at $79.59 on Friday. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The stock has a market capitalization of $33.37 billion, a PE ratio of 13.20, a price-to-earnings-growth ratio of 1.27 and a beta of 0.75. The stock’s fifty day simple moving average is $101.26 and its two-hundred day simple moving average is $115.80. Zoetis Inc. has a 12-month low of $72.38 and a 12-month high of $171.52.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter in the prior year, the company posted $1.48 EPS. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, analysts expect that Zoetis Inc. will post 6.89 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio is currently 35.16%.

Analysts Set New Price Targets

Several analysts have issued reports on ZTS shares. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. UBS Group dropped their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. Stifel Nicolaus dropped their target price on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a research report on Friday, May 22nd. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Finally, Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Six investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and a consensus price target of $133.92.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.